ALNYLAM PHARMACEUTICALS, INC. Stockholders Equity

Quick Answer

ALNYLAM PHARMACEUTICALS, INC. reported Stockholders Equity of $789.18 million for the year ending 2025.

  • ALNYLAM PHARMACEUTICALS, INC. showed an increase of +1,076.3% in Stockholders Equity from 2024 to 2025.
  • This data is from ALNYLAM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
  • XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2014: $954.97 million | Q2 2014: $942.27 million | Q3 2014: $904.48 million | Q1 2015: $1.50 billion | Q2 2015: $1.41 billion | Q3 2015: $1.32 billion | Q1 2016: $1.19 billion | Q2 2016: $1.10 billion | Q3 2016: $1.01 billion | Q1 2017: $830.90 million | Q2 2017: $1.12 billion | Q3 2017: $1.06 billion | Q1 2018: $1.75 billion | Q2 2018: $1.62 billion | Q3 2018: $1.48 billion | Q1 2019: $1.55 billion | Q2 2019: $1.76 billion | Q3 2019: $1.61 billion | Q1 2020: $1.35 billion | Q2 2020: $1.40 billion | Q3 2020: $1.22 billion | Q1 2021: $926.19 million | Q2 2021: $853.36 million | Q3 2021: $755.89 million | Q1 2022: $401.17 million | Q2 2022: $176.04 million | Q3 2022: -$67.64 million | Q1 2023: -$259.24 million | Q2 2023: -$408.13 million | Q3 2023: -$165.87 million | Q1 2024: -$219.27 million | Q2 2024: -$3.07 million | Q3 2024: $32.35 million | Q1 2025: $115.44 million | Q2 2025: $250.59 million | Q3 2025: $233.89 million.
  • Over the full 14 years of available data (2012 to 2025), ALNYLAM PHARMACEUTICALS, INC.'s Stockholders Equity has grown by 488.7%.
  • Historical annual values: Fiscal year 2025: $789.18 million | Fiscal year 2024: $67.09 million | Fiscal year 2023: -$220.64 million | Fiscal year 2022: -$158.22 million | Fiscal year 2021: $588.20 million | Fiscal year 2020: $1.02 billion | Fiscal year 2019: $1.44 billion | Fiscal year 2018: $1.30 billion | Fiscal year 2017: $1.77 billion | Fiscal year 2016: $920.22 million | Fiscal year 2015: $1.26 billion | Fiscal year 2014: $936.27 million | Fiscal year 2013: $270.35 million | Fiscal year 2012: $134.05 million.
  • Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: